Vergoeding 2019-2023 voor ATC-subgroep S01LA : Oculaire antineovascularisatiemiddelen
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021* | 2022* | 2023* | |
|---|---|---|---|---|---|
| S01LA01 Verteporfine | 625.512 | 634.280 | 354.461 | 286.989 | 336.709 |
| S01LA04 Ranibizumab | 21.527.104 | 20.580.810 | 21.151.373 | 18.798.352 | 17.324.338 |
| S01LA05 Aflibercept | 76.727.439 | 72.250.190 | 87.618.452 | 95.114.561 | 109.478.037 |
| S01LA06 Brolucizumab | . | 31.243 | 295.971 | 473.345 | 508.362 |
| S01LA09 Faricimab | . | . | . | . | 851.990 |
| Totaal | 98.880.056 | 93.496.523 | 109.420.256 | 114.673.247 | 128.499.435 |